Dengue and chikungunya in travelers: Recent updates

Current Opinion in Infectious Diseases

Volumn 25, Issue 5, 2012, Pages 523-529

  Chen, Lin H ^a,b   Wilson, Mary E ^c  

^a MOUNT AUBURN HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Aedes; chikungunya; dengue; flavivirus; mosquito borne infections; travelers; Wolbachia

Indexed keywords

ALPHA INTERFERON; DENGUE VACCINE; NONSTEROID ANTIINFLAMMATORY AGENT; RIBAVIRIN;

AEDES ALBOPICTUS; AFRICA; ARTHRALGIA; CHIKUNGUNYA; CHIKUNGUNYA ALPHAVIRUS; CLINICAL FEATURE; DENGUE; DENGUE VIRUS; EMPORIATRICS; HUMAN; IMMUNE RESPONSE; NONHUMAN; PATHOGENESIS; REVIEW; VIRUS TRANSMISSION; WOLBACHIA;

ALPHAVIRUS INFECTIONS; ANIMALS; ANTIVIRAL AGENTS; DENGUE; DISEASE OUTBREAKS; DISEASE VECTORS; HUMANS; MOSQUITO CONTROL; TRAVEL;

EID: 84865862574     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328356ffd5     Document Type: Review

References (72)

1. Chen LH, Wilson ME. Dengue and chikungunya infections in travelers. Curr Opin Infect Dis 2010; 23:438-444.
2. Simmons CP, Farrar JJ, Chau NV, Wills B. Current concepts: dengue. N Engl J Med 2012; 366:1423-1432.
3. Burt FJ, Rolph MS, Rulli NE, et al. Chikungunya: a re-emerging virus. Lancet 2012; 379:662-671.
4. Pan American Health Organization. Preparedness and response for chikungunya virus: introduction in the Americas. Washington, DC: PAHO; 2011. Available at http://new.paho.org/hq/index.php?option1/4com-content&task1/ 4view& id1/46464&Itemid1/41926. [Accessed 22 April 2012]
5. Vazeille M, Mousson L, Martin E, Failloux A-B. Orally co-infected Aedes albopictus from La Reunion Island, Indian Ocean, can deliver both dengue and chikungunya infectious viral particles in their saliva. PLoS NTD 2010; 4:e706.
6. Werner D, Kronefeld M, Schaffner F, Kampen H. Two invasive mosquito species, Aedes albopictus and Aedes japonicas japonicas, trapped in southwest Germany, July to August 2011. Euro Surveill 2012; 17:p111/420067.
7. Medlock JM, Hansford KM, Schaffner F, et al. A review of the invasive mosquitoes in Europe: ecology, public health risks, and control options. Vector Borne Zoonotic Dis 2012; 12:435-447.
8. Senn N, Luang-Suarkia D, Manong D, et al. Contribution of dengue fever to the burden of acute febrile illnesses in Papua New Guinea: an age-specific prospective study. Am J Trop Med Hyg 2011; 85:132-137.
9. Fernández J, Vera L, Tognarelli J, et al. Detection of dengue virus type 4 in Easter Island, Chile. Arch Virol 2011; 156:1865-1868.
10. Amarasinghe A, Kuritsk JN, Letson GW, Margolis HS. Dengue virus infection in Africa. Emerg Infect Dis 2011; 17:1349-1354.
11. Mease LE, Coldren RL, Musila LA, et al. Seroprevalence and distribution of arboviral infections among rural Kenyan adults: a cross-sectional study. Virol J 2011; 8:371.
12. Sutherland LJ, Cash AA, Huang YJ, et al. Serologic evidence of arboviral infections among humans in Kenya. Am J Trop Med Hyg 2011; 85:158-161.
13. Hertz JT, Munishi OM, Ooi EE, et al. Chikungunya and dengue fever among hospitalized febrile patients in northern Tanzania. Am J Trop Med Hyg 2012; 86:171-177.
14. Baaten GG, Sonder GJ, Zaaijer HL, et al. Travel-related dengue virus infection, the Netherlands, 2006-2007. Emerg Infect Dis 2011; 17:821-828.
15. Gould EA, de Lamballerie PGX, Charrel RN. First cases of autochthonous dengue fever and chikungunya fever in France: from bad dream to reality. Clin Microbiol Infect 2010; 16:1702-1704.
16. Gjenero-Margan I, Aleraj B, Krajcar D, et al. Autochthonous dengue fever in Croatia, August-September 2010. Euro Surveill 2011; 16:pii1/419805. Available online http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19805. [Accessed 23 April 2012]
17. Pierro A, Varani S, Rossini G, et al. Imported cases of dengue virus infection: Emilia-Romagna, Italy, 2010. Clin Microbiol Infect 2011; 17:1349-1352.
18. Burdino E, Milia MG, Sergi G, et al. Diagnosis of dengue fever in North West Italy in travelers from endemic areas: a retrospective study. J Clin Virol 2011; 51:259-263.
19. Allwinn R. Significant increase in travel-associated dengue fever in Germany. Med Microbiol Immunol 2011; 200:155-159.
20. Franco L, Palacios G, Martinez JA, et al. First report of sylvatic DENV-2-associated dengue hemorrhagic fever in West Africa. PLoS Negl Trop Dis 2011; 5:e1251.
21. Centers for Disease Control and Prevention (CDC). Dengue virus infections among travelers returning from Haiti-Georgia and Nebraska, October 2010. MMWR Morb Mortal Wkly Rep 2011; 60:914-917.
22. Radke EG, Gregory CJ, Kintziger KW, et al. Dengue outbreak in Key West, Florida, USA, 2009. Emerg Infect Dis 2012; 18:135-137.
23. Laoprasopwattana K, Kaewjungwad L, Jarumanokul R, Geater A. Differential diagnosis of chikungunya, dengue viral infection and other acute febrile illnesses in children. Pediatr Infect Dis J 2012; 31:459-463.
24. Jardim DL, Tsukumo DM, Angerami RN, et al. Autoimmune features caused by dengue fever: a case report. Braz J Infect Dis 2012; 16:92-95.
25. Araú jo FM, Araú jo MS, Nogueira RM, et al. Central nervous system involvement in dengue: a study in fatal cases from a dengue endemic area. Neurology 2012; 78:736-742.
26. Lee IK, Liu JW, Yang KD. Fatal dengue hemorrhagic fever in adults: emphasizing the evolutionary prefatal clinical and laboratory manifestations. PLoS Negl Trop Dis 2012; 6:e1532.
27. Vasanwala FF, Puvanendran R, Fook-Chong S, et al. Could peak proteinuria determine whether patient with dengue fever develop dengue hemorrhagic/dengue shock syndrome?-a prospective cohort study. BMC Infect Dis 2011; 11:212.
28. Falconar AK, Romero-Vivas CM. Simple prognostic criteria can definitively identify patients who develop severe versus non-severe dengue disease, or have other febrile illnesses. J Clin Med Res 2012; 4:33-44.
29. Brasier AR, Ju H, Garcia J, et al., Venezuelan Dengue Fever Working Group. A three-component biomarker panel for prediction of dengue hemorrhagic fever. Am J Trop Med Hyg 2012; 86:341-348.
30. Thein TL, Leo YS, Lee VJ, et al. Validation of probability equation and decision tree in predicting subsequent dengue hemorrhagic fever in adult dengue inpatients in Singapore. Am J Trop Med Hyg 2011; 85:942-945.
31. Whitehorn J, Simmons CP. The pathogenesis of dengue. Vaccine 2011; 29:7221-7228.
32. Anderson KB, Gibbons RV, Thomas SJ, et al. Preexisting Japanese encephalitis virus neutralizing antibodies and increased symptomatic dengue illness in a school-based cohort in Thailand. PLoS Negl Trop Dis 2011; 5:e1311.
33. Duyen HT, Ngoc TV, Ha do T, et al. Kinetics of plasma viremia and soluble nonstructural protein 1 concentrations in dengue: differential effects according to serotype and immune status. J Infect Dis 2011; 203:1292-1300.
34. Mathew A, West K, Kalayanarooj S, et al. B-cell responses during primary and secondary dengue virus infections in humans. J Infect Dis 2011; 204:1514-1522.
35. Hatch S, Endy TP, Thomas S, et al. Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection. J Infect Dis 2011; 203:1282-1291.
36. Duong V, Ly S, Lorn Try P, et al. Clinical and virological factors influencing the performance of a NS1 antigen-capture assay and potential use as a marker of dengue disease severity. PLoS Negl Trop Dis 2011; 5:e1244.
37. Fry SR, Meyer M, Semple MG, et al. The diagnostic sensitivity of dengue rapid test assays is significantly enhanced by using a combined antigen and antibody testing approach. PLoS Negl Trop Dis 2011; 5:e1199.
38. Puttikhunt C, Prommool T, U-thainual N, et al. The development of a novel serotyping-NS1-ELISA to identify serotypes of dengue virus. J Clin Virol 2011; 50:314-319.
39. Chuansumrit A, Chaiyaratana W, Tangnararatchakit K, et al. Dengue nonstructural protein 1 antigen in the urine as a rapid and convenient diagnostic test during the febrile stage in patients with dengue infection. Diagn Microbiol Infect Dis 2011; 71:467-469.
40. Yap G, Sil BK, Ng LC. Use of saliva for early dengue diagnosis. PLoS Negl Trop Dis 2011; 5:e1046.
41. Stramer SL, Linnen JM, Carrick JM, S, et al. Dengue viremia in blood donors identified by RNA and detection of dengue transfusion transmission during the 2007 dengue outbreak in Puerto Rico. Transfusion 2012. doi:10.1111/j.1537- 2995.2012.03566.x. [Epub ahead of print]
42. Petersen LR, Tomashek KM, Biggerstaff BJ. Estimated prevalence of dengue viremia in Puerto Rican blood donations, 1995 through 2010. Transfusion 2012. doi: 10.1111/j.1537-2995.2011.03529.x. [Epub ahead of print].
43. Komalamisra N, Srisawat R, Phanbhuwong T, Oatwaree S. Insecticide susceptibility of the dengue vector, Aedes aegypti (L.) in Metropolitan Bangkok. Southeast Asian J Trop Med Public Health 2011; 42:814-823.
44. Marcombe S, Mathieu RB, Pocquet N, et al. Insecticide resistance in the dengue vector Aedes aegypti from Martinique: distribution, mechanisms and relations with environmental factors. PLoS One 2012; 7:e30989.
45. Coller BA, Clements DE. Dengue vaccines: progress and challenges. Curr Opin Immunol 2011; 23:391-398.
46. Iturbe-Ormaetxe I, Walker T, O'Neill SL. Wolbachia and the biological control of mosquito-borne disease. EMBO Rep 2011; 12:508-518.
47. Hoffmann AA, Montgomery BL, Popovici J, et al. Successful establishment of Wolbachia in Aedes populations to suppress dengue transmission. Nature 2011; 476:454-457.
48. Walker T, Johnson PH, Moreira LA, et al. The wMel Wolbachia strain blocks dengue and invades caged Aedes aegypti populations. Nature 2011; 476:450-453.
49. Pan X, Zhou G, Wu J, et al. Wolbachia induces reactive oxygen species (ROS)-dependent activation of the Toll pathway to control dengue virus in the mosquito Aedes aegypti. Proc Natl Acad Sci USA 2012; 109:E23-E31.
50. Blagrove MS, Arias-Goeta C, Failloux AB, Sinkins SP. Wolbachia strain wMel induces cytoplasmic incompatibility and blocks dengue transmission in Aedes albopictus. Proc Natl Acad Sci USA 2012; 109:255-260.
51. Simon F, Javelle E, Oliver M, et al. Chikungunya virus infection. Curr Infect Dis Rep 2011; 13:218-228.
52. Wu D, Wu J, Zhang Q, et al. Chikungunya outbreak in Guangdong Province, China, 2010. Emerg Infect Dis 2012; 18:493-495.
53. Chaves Tdo S, Pellini AC, Mascheretti M, et al. Travelers as sentinels for chikungunya fever, Brazil. Emerg Infect Dis Letter 2012; 18:529-530.
54. Charrel RN, de Lamballerie X, Raoult D. Seasonality of mosquitoes and chikungunya in Italy. Lancet Infect Dis 2008; 8:5-6.
55. Tsetsarkin KA, Chen R, Leal G, et al. Chikungunya virus emergence is constrained in Asia by lineage-specific adaptive landscapes. Proc Natl Acad Sci USA 2011; 108:7872-7877.
56. Renault P, Solet J-L, Sissoko D, et al. A major epidemic of chikungunya virus infection on Reunion Island, France 2005-2006. Am J Trop Med Hyg 2007; 77:727-731.
57. Murray C, Rosenfeld LC, Lim SS, et al. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 2012; 379:413-431.
58. Chopra A, Anuradha V, Lagoo-Joshi V, et al. Chikungunya virus aches and pains: an emerging challenge. Arthritis Rheum 2008; 58:2921-2922.
59. Jaffar-Bandjee, Das T, Hoarau JJ, et al. Chikungunya virus takes centre stage in virally induced arthritis: possible cellular and molecular mechanisms to pathogenesis. Microbes Infect 2009; 11:1206-1288.
60. Schwartz O, Albert ML. Biology and pathogenesis of chikungunya virus. Nat Rev 2010; 8:491-500.
61. Sissoko D, Malvy D, Ezzedine K, et al. Postepidemic chikungunya disease on Reunion Island: course of rheumatic manifestations and associated factors over a 15-month period. PLoS NTD 2009; 3:e389.
62. Hoarau J-J, Jaffar Bandjee M-C, Kreibich Trotot P, et al. Persistent chronic inflammation and infection by chikungunya arthritogenic alphavirus in spite of a robust host immune response. J Immunol 2010; 184:5914-5927.
63. Chow A, Her Z, Long EKS, et al. Persistent arthralgia induced by chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor. J Infect Dis 2011; 203:149-157.
64. Win MK, Chow A, Dimatatac F, et al. Chikungunya fever in Singapore: acute clinical laboratory features and factors associated with persistent arthralgia. J Clin Virol 2010; 49:111-114.
65. Kelvin AA, Banner D, Silvi G, et al. Inflammatory cytokine expression is associated with chikungunya virus resolution and symptom severity. PLoS NTD 2011; 5:e1279.
66. Wauquier N, Becquart P, Nkoghe D, et al. The acute phase of chikungunya virus infection in humans is associated with strong innate immunity and T CD8 cell activation. J Infect Dis 2011; 204:115-123.
67. Labadie K, Larcher T, Joubert C, et al. Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages. J Clin Invest 2010; 120:894-906.
68. Ziad A, Rulli NE, Folph MS, et al. Disease exacerbation by etanercept in a mouse model of alphaviral arthritis and myositis. Arthritis Rheum 2011; 63:488-491.
69. Petersen LR, Stramer SL, Powers AM. Chikungunya virus: possible impact on transfusion medicine. Transfusion Med Rev 2010; 24:15-21.
70. Briolant S, Garin D, Scaramizzino N, et al. In vitro inhibition of chikungunya and Semliki forest viruses replication by antiviral compounds: synergistic effect of interferon-alpha and ribavirin combination. Antiviral Res 2004; 61:111-117.
71. Rulli NE, Rolph MS, Srikiatkhachorn A, et al. Protection from arthritis and myositis in a mouse model of acute chikungunya virus disease by Bindarit, an inhibitor of monocyte chemotactic protein-1-synthesis. J Infect Dis 2011; 204:1026-1030.
72. Couderc T, Khandoudi N, Grandadam M, et al. Prophylaxis and therapy for chikungunya virus infection. J Infect Dis 2009; 200:516-523.